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June Supplement 201162S Abstracts1 had major amputation (11.1%) and 2 were managed
expectantly. Of the 11 failed PC grafts 4(37%) underwent
major amputation, 4 had new bypasses and 3weremanaged
expectantly.
Conclusions: For patients with inadequate SSGSV,
prosthetic conduit is equivalent to alternative vein sources
in terms of graft patency and limb salvage rates for below-
knee popliteal bypass targets.
Primary
Patency
(%)
Assisted
Primary
Patency
(%)
Secondary
Patency
(%)
Limb
Salvage
(%)
Post-op
Coumadin
Usage (%)
Alternative
Vein
54.9  9.9 68.5  9.5 68.4  9.5 96.4  3.6 27.3
Prosthetic
Conduit
54.6  10.5 56  10.6 68.8  9.1 86.0  6.3 61.5
P-value 0.5 0.2 0.5 0.08 0.001
Author Disclosures: N. R. Barshes: Nothing to disclose;
M. Belkin: Nothing to disclose; J. T. McPhee: Nothing to
disclose; L. L. Nguyen: Nothing to disclose; C. K. Ozaki:
Nothing to disclose.
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Plasmin (Human) TAL-05-00018 Demonstrates a
Good Safety Profile in Patients with Acute Peripheral
Arterial Occlusion
Anthony J. Comerota1, David Fineberg2, Richard Shlan-
sky-Goldberg3, Chunqin Deng4, Victor J. Marder5. 1Jobst
Vascular Center, Toledo, OH; 2Talecris Biotherapeutics,
Research Triangle Park, NC; 3Hospital of the University of
Pennsylvania, Philadelphia, PA; 4Talecris Biotherapeutics,
Research Triangle Park, NC; 5David Geffen School of
Medicine at UCLA, Los Angeles, CA
Objectives: Plasmin is a direct-acting thrombolytic
that has superior hemostatic safety compared to plasmino-
gen activator in preclinical studies. Here, we report safety
data of plasmin in patients with acute peripheral arterial
occlusion (aPAO).
Methods: This was an open-label, Phase I, dose esca-
lation study of Plasmin (human) TAL-05-00018 (Talecris
Biotherapeutics) in patients with SVS Class I or IIa acute
limb ischemia. Sequential 10-13 patient cohorts received a
single,5-hour intrathrombus dose of Plasmin (25 to 175
mg) by multi-slit catheter using manual pulse-spray injec-
tions followed by continuous infusion. Safety was assessed
with clinical evaluations and monitoring of plasma concen-
trations of fibrinogen and alpha 2-antiplasmin inhibitor at
end of plasmin treatment and on days 1-2, 7, 14 and 30.
Results: Of 83 patients enrolled, 19 (22.9%) had seri-
ous adverse events (SAEs) and 57 (68.7%) had treatment-
emergent (TE) adverse events (AEs). Two patients died
(myocardial infarction, sepsis). Four patients had a major
bleeding event and 14 had minor bleeding events. None of
the SAEs, deaths or bleeding events were reported by
investigators to be Plasmin-related. TEAEs, SAEs, and pleeding events did not increase with Plasmin dose. Mean
ost-treatment fibrinogen nadirs were similar at all plasmin
osages (350 - 440 mg/dL). Furthermore, alpha 2-anti-
lasmin inhibitor and fibrinogen levels were similar in
atients with and without bleeding events.
Conclusions: Plasmin treatment (up to 175 mg) of
atients with aPAO had a favorable safety profile, notably
bsence of treatment-related bleeding and maintenance
f normal fibrinogen concentration. These results sup-
ort further clinical trials of Plasmin for treatment of
PAO.
uthor Disclosures: A. J. Comerota: Talecris Biothera-
eutics,Consulting fees or other remuneration (payment)
alecris Biotherapeutics, Research Grants;C. Deng: Talec-
is Biotherapeutics, Employment (full or part-time); D.
ineberg: Talecris Biotherapeutics, Employment (full or
art-time); V. J. Marder: Talecris Biotherapeutics,Con-
ulting fees or other remuneration (payment) Talecris Bio-
herapeutics,Research Grants; R. Shlansky-Goldberg:
alecris Biotherapeutics, Consulting fees or other remu-
eration (payment)Talecris Biotherapeutics, Research
rants.
S126.
ound Infection after Lower Extremity Bypass In-
reases Hospital Resource Utilization But is Not Asso-
iated with Negative Long-Term Outcomes
effrey Kalish1, Alik Farber1, Andres Schanzer2, Gheorghe
oros3, Denis Rybin3, Kevin Tan1, Naomi Hamburg1,
obert Eberhardt1, Jack Cronenwett4. 1Boston Medical
enter, Boston,MA; 2University of Massachusetts Medical
enter,Worcester,MA; 3BostonUniversity School of Pub-
ic Health, Boston, MA; 4Dartmouth-Hitchcock Medical
enter, Lebanon, NH
Objectives: Wound infection (WI) after lower extrem-
ty bypass (LEB) is reported in 5-22% of cases. This com-
lication has been cited by proponents of endovascular
evascularization as a reason to avoid LEB. Although nu-
erous studies have attempted to define predictive risk
actors, long-term effects of WI after LEB have not been
lucidated.
Methods: Using the Vascular Study Group of New
ngland database(2003-2009), we examined 2721 consec-
tive LEB procedures performed by 57 surgeons at aca-
emic and community hospitals. The cohort was stratified
y indication: intermittent claudication (IC) and critical
imb ischemia (CLI). In-hospital WI required documenta-
ion of positive cultures or antibiotic treatment. Primary
ndpoints were ambulation at hospital discharge, 1-year
reedom from major amputation, and 1-year primary
atency.
Results: WI rates were 4.5% (33/734) for IC and 5.5%
109/1987) for CLI. Mean length of stay (LOS) was
ignificantly greater with WI (IC: 3.8 vs 10.1 days,
0.001; CLI: 8.9 vs 13.6 days, p0.001). No signifi-
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Volume 53, Number 17S Abstracts 63Scant differences existed in discharge ambulation (WI 91.6%
vs 91.9%, p0.879), 1-year amputation (WI 12.3% vs
8.9%, p0.226), or 1-year primary patency (WI 64.4% vs
70.8%, p0.297). On multivariate analysis, predictors of
WI in IC included COPD (OR 2.24, 95% CI 1.08-4.62)
and age55 (OR 2.6, 95% CI 1.22-5.55). In CLI, predic-
tors included tibial versus popliteal target (OR 1.64, 95%CI
1.09-2.45) and age55 (OR 1.74, 95% CI 1.0-3.04).
Conclusions: In this large contemporary cohort of
patients undergoing LEB, WI rates were low and did not
have significant long-term implications. While hospital re-
source utilization secondary to prolonged LOS was in-
creased, outcomes related to function, graft patency, and
limb salvage were not affected. WI is a self-limiting compli-
cation and should not significantly impact the decision of
whether or not to perform a LEB.
Author Disclosures: J. Cronenwett: Nothing to disclose;
G. Doros: Nothing to disclose; R. Eberhardt: Nothing to
disclose; A. Farber: Nothing to disclose; N. Hamburg:
Nothing to disclose; J. Kalish: Nothing to disclose; D.
Rybin: Nothing to disclose; A. Schanzer: Nothing to
disclose; K. Tan: Nothing to disclose.
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Comparing Patency and Salvage Rates between Multi-
ple Ipsilateral Iliac Artery Stents and Isolated Iliac
Artery Stents: Beyond TASC II
Rachel C. Danczyk1, Erica L. Mitchell1, Sharon G. Kry-
ger1, Chad Burk1, Sarguni Singh1, Timothy K. Liem1,
Gregory J. Landry1, James M. Edwards2, Bryan D. Pe-
tersen3, Gregory L. Moneta1. 1Division Vascular Surgery,
OregonHealth& ScienceUniversity, Portland, OR; 2Port-
land VAMedical Center, Portland, OR; 3The Dotter Insti-
tute, Oregon Health & Science University, Portland, OR
Objectives: Endovascular stents are accepted therapy
for TASC A, B and some C lesions. Surgery is the
recommended therapy for patients with TASC D lesions
including those with both ipsilateral common iliac (CIA)
and external iliac artery (EIA) stenoses/occlusion. This
study compares anatomic patency and operative salvage
rates for combined ipsilateral CIA and EIA stenting
(TASC D) versus CIA or EIA stents alone (TASC A, B
or C).
Methods: All patients (n481) who underwent iliac
artery stenting at a single institution between 1998 and
2010 were identified. Patient comorbidities and outcomes
were retrospectively reviewed and analyses were performed
using multivariate regression and Kaplan-Meier curves.
Results: There were 325 extremities with CIA stents,
173 with EIA stents, and 137 with both CIA and EIA
stents. There was no significant difference in demographics,
comorbidities, or treatment indications between groups.
During follow-up, 160 patients died, 83 underwent endo-
vascular reintervention, and 34 required salvage operation.
Mean times to follow-up, death, reintervention, and oper- ctive salvage were 2.50.1, 5.50.3, 7.00.6, and
.80.5 years, respectively. CIA and EIA stenting in com-
ination was not a predictor of death, reintervention, or
alvage operation. Survival, reintervention-free survival,
nd salvage operation-free survival were similar between
hose who hadCIA or EIA stents alone and those with both
IA and EIA stents (all p0.05).
Conclusions: CIA stents, EIA stents, and the combi-
ation of ipsilateral CIA and EIA stents have similar out-
omes. Salvage operations for iliac artery stent failure are
ncommon and not influenced by the location or extent of
liac artery stent placement. This study suggests that a more
ggressive approach with total endovascular management
or some TASCD lesion is acceptable. TASC II recommen-
ations for endovascular therapy for aorto-iliac disease
hould be extended to consider selected patients with ipsi-
ateral CIA and EIA stenoses/occlusion.
uthor Disclosures: C. Burk: Nothing to disclose; R. C.
anczyk: Nothing to disclose; J. M. Edwards: Nothing to
isclose; S. G. Kryger: Nothing to disclose; G. J. Landry:
othing to disclose; T. K. Liem: Nothing to disclose; E. L.
itchell: Nothing to disclose; G. L. Moneta: Nothing to
isclose; B. D. Petersen: Nothing to disclose; S. Singh:
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ve Thott1, JonasMalmstedt1, Fredrik Granath2, CarlWahl-
ren1. 1Department of Vascular Surgery, Karolinska Institute
nd Karolinska University Hospital, Stockholm, Sweden;
Clinical Epidemiology Unit, Department of Internal Medi-
ine, Karolinska Institute, Stockholm, Sweden
Objectives: The use of antiplatelet agents to improve
esults of peripheral angioplasty and stenting is not well
efined. The purpose of this study was to analyze the
ontemporary use of antithrombotic therapy and the
ffect on outcome after endovascular femoropopliteal
nterventions.
Methods: All primary endovascular interventions in
he femoropopliteal arteries between 2006 and 2008
ere identified from the National Vascular Registry
Swedvasc). The cohort was cross-linked with the Na-
ional Pharmaceutical Registry providing information
bout post-procedure antithrombotic treatment. Demo-
raphics, major amputation and death were analyzed
sing logistic regression models and Kaplan-Meier sur-
ival analysis.
Results: 3281 patients underwent endovascular inter-
ention in the femoropopliteal segment (balloon angio-
lasty (PTA) 68%; stent/stentgraft 18%; subintimal angio-
lasty (SAP) 14%). Post-procedure antithrombotic therapy
as: ASA (acetylsalicylic acid) 43%, clopidogrel 5%, ASA-
lopidogrel 24%, warfarin 4%, or other 24%. Dominating
